Patients clinically diagnosed with infections (including pulmonary infections, skin/soft tissue infections, intra-abdominal infections, bloodstream infections, etc.).
Conditions
Interventions
Eravacycline treatment group:NA
Sponsors
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with a clinical diagnosis of infection; 2. Patients who received eravacycline treatment for more than 3 days.
Exclusion criteria
Exclusion criteria: 1. Enrollment in any other clinical trial or non-treatment-naïve individuals; 2. Patients in a moribund state; 3. Pathogen testing reveals that the causative bacteria are not within the expected spectrum of activity of eravacycline (e.g., Pseudomonas aeruginosa, fungi); 4. Missing critical study data in the hospital medical record system, making outcome assessment impossible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical improvement rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reaction events;Microbial clearance rate;All-cause mortality rate and infection-related mortality rate; | — |
Countries
China
Contacts
Public ContactQiu Kaifeng
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Outcome results
None listed